21 and older, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Physical Health of Patient at EnrollmentPrimary· At enrollment
From all patients in the intervention and control arms, we will collect patient on physical health using the Functional Assessment of Cancer Therapy - disease specific.
FACT-G is a 27-item questionnaire designed to measure four domains of health-related quality of life in cancer patients based on the past 7 days: physical, social, emotional, and functional well-being (score range is 1-108; higher scores indicate better quality of life). The scale's ability to discriminate patients on the basis of performance status and hospitalization status supports its sensitivity. It has also demonstrated
Group
Value
95% CI
Intervention
77.2
± 21.3
Control Arm
82.7
± 16.7
Behavioral Health of PatientPrimary· At time of enrollment
From all patients in the intervention and control arms, we will collect patient self-report data on problem solving skills,using the Social Problem-Solving Inventory-Revised (SPSI-R)
SPSI-R is a 25-item self-report tool linked to a multidimensional model of problem-solving skills. SPSI-R:S has been demonstrated to have strong reliability and validity estimates. The scale includes 5 sub-scales grouped into two decision-making styles: constructive (Positive Problem Orientation and Rational Problem Solving) and dysfunctional (Negative Problem Orientation, Impulsivity/ Carelessness, and Avoidance
Group
Value
95% CI
Intervention
12.2
± 3.7
Control Arm
11.7
± 3.7
Mean Change in Physical Health From Baseline to 3-monthsPrimary· At 3 months
From all patients in the intervention and control arms, we will collect patient on physical health using the Functional Assessment of Cancer Therapy - Disease Specific (FACT)
FACT-G is a 27-item questionnaire designed to measure four domains of health-related quality of life in cancer patients based on the past 7 days: physical, social, emotional, and functional well-being (score range is 1-108; higher scores indicate better quality of life). The scale's ability to discriminate patients on the basis of performance status and hospitalization status supports its sensitivity. It has also demonst
baseline
Group
Value
95% CI
Intervention
77.2
± 21.3
Control Arm
82.7
± 16.7
3-months
Group
Value
95% CI
Intervention
82.4
± 19.6
Control Arm
82.4
± 20.2
Mean Change Physical Health of Patient at 12 MonthsPrimary· At 12 months
From all patients in the intervention and control arms, we will collect patient on physical health using the Functional Assessment of Cancer Therapy (FACT)
FACT-G is a 27-item questionnaire designed to measure four domains of health-related quality of life in cancer patients based on the past 7 days: physical, social, emotional, and functional well-being (score range is 1-108; higher scores indicate better quality of life). The scale's ability to discriminate patients on the basis of performance status and hospitalization status supports its sensitivity. It has also demonstrated sensitivity t
baseline
Group
Value
95% CI
Intervention
77.2
± 21.3
Control Arm
82.7
± 16.7
12-months
Group
Value
95% CI
Intervention
87.1
± 21.5
Control Arm
82.3
± 18.9
Mean Change in Behavioral Health of Patient at 3 MonthsPrimary· At 3 months
From all patients in the intervention and control arms, we will collect patient self-report data on problem solving skills,using the Social Problem-Solving Inventory-Revised (SPSI-R)
SPSI-R is a 25-item self-report tool linked to a multidimensional model of problem-solving skills. SPSI-R:S has been demonstrated to have strong reliability and validity estimates. The scale includes 5 sub-scales grouped into two decision-making styles: constructive (Positive Problem Orientation and Rational Problem Solving) and dysfunctional (Negative Problem Orientation, Impulsivity/ Carelessness, and Avoidance
baseline
Group
Value
95% CI
Intervention
12.2
± 3.7
Control Arm
11.7
± 3.7
3-months
Group
Value
95% CI
Intervention
13.4
± 3.8
Control Arm
11.6
± 4.2
Mean Change in Behavioral Health of Patient at 12 MonthsPrimary· At 12 months
From all patients in the intervention and control arms, we will collect patient self-report data on problem solving skills,using the Social Problem-Solving Inventory-Revised (SPSI-R)
SPSI-R is a 25-item self-report tool linked to a multidimensional model of problem-solving skills. SPSI-R:S has been demonstrated to have strong reliability and validity estimates. The scale includes 5 sub-scales grouped into two decision-making styles: constructive (Positive Problem Orientation and Rational Problem Solving) and dysfunctional (Negative Problem Orientation, Impulsivity/ Carelessness, and Avoidance
baseline
Group
Value
95% CI
Intervention
12.2
± 3.7
Control Arm
11.7
± 3.7
12-months
Group
Value
95% CI
Intervention
13.8
± 3.1
Control Arm
11.7
± 4.5
Healthcare Utilization of PatientsPrimary· At 12 months
From all patients in the intervention and control arms, we will collect patient self-report data by asking the patients about their healthcare utilization since the last study assessment including primary care, specialist and ED visits, use of supportive services and any hospital stays.
Number of Hospital Visits
Group
Value
95% CI
Intervention
0.0
± 0.0
Control Arm
0.4
± 0.9
Number of Emergency Room Visits
Group
Value
95% CI
Intervention
0.0
± 0.0
Control Arm
0.3
± 0.9
Number of Ambulatory Services Used
Group
Value
95% CI
Intervention
6.5
± 4.7
Control Arm
5.7
± 3.9
Sponsor's own description
The aim of this 2-year study will assess the acceptability and feasibility of offering Problem Solving Skills Therapy (PSST) to cancer survivors and their caregivers focusing on the highest risk patients with distress.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06645015 — The AIDPRO-CRC Trial
· NA
· recruiting
NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
· Phase 1, PHASE2
· recruiting
NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
· Phase 2
· recruiting
NCT06880055 — Shield Post-Approval Study Protocol
· recruiting
NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy
· NA
· recruiting
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
· Phase 1
· not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I
· Phase 2
· not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
· Phase 2
· not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
· EARLY_PHASE1
· not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma
· Phase 1
· withdrawn
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 28 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03567850.